GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Cyclically Adjusted Price-to-FCF

Molecular Partners AG (XSWX:MOLN) Cyclically Adjusted Price-to-FCF : (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Molecular Partners AG Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Molecular Partners AG's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Cyclically Adjusted Price-to-FCF Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Molecular Partners AG Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Molecular Partners AG's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Molecular Partners AG's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Cyclically Adjusted Price-to-FCF falls into.



Molecular Partners AG Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Molecular Partners AG's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec23 is calculated as:

For example, Molecular Partners AG's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec23 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=-1.825/106.4612*106.4612
=-1.825

Current CPI (Dec23) = 106.4612.

Molecular Partners AG Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 -0.777 100.704 -0.821
201512 1.285 99.386 1.376
201612 -1.786 99.380 -1.913
201712 -1.942 100.213 -2.063
201812 -2.047 100.906 -2.160
201912 -0.143 101.063 -0.151
202012 -1.227 100.241 -1.303
202112 -2.976 101.776 -3.113
202212 3.522 104.666 3.582
202312 -1.825 106.461 -1.825

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Molecular Partners AG  (XSWX:MOLN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Molecular Partners AG Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Industry
Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus